Anemia is a common complication in post-lung transplant recipients. Although its mechanism is often multifactorial, clinicians should investigate an eventual underlying explanation to provide the best care. Among the reasons for anemia in lung transplant recipients, blood loss should be thought within the first few days after surgery. Later on, immune-mediated mechanisms, microangiopathic hemolytic anemia and reduction in red blood cell production mediated by viruses, drugs and infiltrative disorders prevail. This article reviews the mechanisms of anemia in post-lung transplant patients and provides an algorithm towards its approach.
Anemia is not a diagnosis; its appearance is usually related to an underlying cause. The presence of anemia is often found after solid organ transplantation, particularly renal, liver, heart and lung transplantation. The cause of anemia is likely multifactorial, however, identification of the producing mechanism carries important implications as the treatment may vary considerably. In many studies, the definition of anemia is based on the one suggested by the WHO expert committee. 1 In this report, anemia is defined as hemoglobin lower than 12 g/dL in men and 13 g/ dL in women. Despite the fact that several classifications of anemia have been described, the pathophysiologic classification will be the one used in this review. The aforementioned classification distinguishes two groups (a) Loss of red blood cells (RBCs) and/or increase in destruction and (b) decrease in production of RBCs (Table 1 ).
Mechanism of anemia Blood loss and increase in destruction
Blood loss. During the first 2 weeks following lung transplantation, the greatest causes of morbidity are related to the transplant operation itself. Transplant recipients frequently have pleural adhesions and hypertrophy of the bronchial circulation due to the inflammation associated with the underlying pulmonary disease. These changes can produce significant hemorrhage following the removal of the recipient's native lung. 2 A report of perioperative complications of lung transplantation in patients with emphysema and fibrosis states that the incidence of hemorrhage from 1992 to 2002 was 13.3% in patients with pulmonary fibrosis and 16.9% in patients with emphysema. 3 Further studies evaluated the presence of acute and chronic pleural complications after lung transplantation. One study reported that 9 out of 56 (16%) double lung and 6 out of 44 (13%) single lung transplant patients presented hemothorax post surgery. 4 The effusion post-lung transplantation is characterized by pleural drainage that is hemorrhagic in most patients. This effusion tends to self-limit and usually becomes serous after 7 days post surgery. Hence, the presence of hemorrhagic pleural effusion that persists over 7 days post-lung transplantation warrants further investigation and eventual re-exploration. 4 Immune-mediated hemolysis. Hemolysis caused by immune mechanisms is a well-recognized complication of solid organ transplantation. 5 This type of anemia is common in recipients of ABO and D incompatible grafts. The mechanism of hemolysis involves the production of antibodies against the recipient's RBCs by immunocompetent memory B lymphocytes coming from the donor. 6 The aforementioned sequence of events is known as the passenger lymphocyte syndrome (PLS) and its frequency increases with the amount of lymphoid tissue transplanted with the graft. PLS occurs more often in patients with heart and lung transplant and less frequently in patients with liver and kidney transplant. 7 Some reports describe an incidence of PLS as high as 55%-68%. 6, [8] [9] [10] Antibodies against the recipient's RBCs and involved in PLS become evident 5 to 15 days post transplantation 5,9 and are usually undetectable by 3 months post surgery. The clinical presentation of this hemolysis is usually abrupt in onset and its severity is determined by several factors, including the amount of tissue transplanted and the rapid rise in antibody titer in the recipients after transplant. Rarely, PLS may be associated with 'bystander immune hemolysis,' in which RBCs that are negative for the antigen are also destroyed. The mechanism is not clear but the massive RBC destruction is thought to be complement mediated. 9 There have been reports of immune-mediated hemolytic anemia as a drug-induced phenomenon that was described with the use of calcineurin inhibitors, such as cyclosporine and tacrolimus. 11 These medications have selective effect on T-cell function, sparing B-cell activity. Therefore, a secondary immune response manifested by the production of antibodies and eventual autoimmune hemolytic anemia is developed. 11 Some patients, who require induction therapy due to high Panel Reactive Antibody (PRA) and receive antilymphocyte globulin, may develop hemolytic anemia. A passive transfer of antibodies with the antilymphocyte globulin preparation might be responsible for this reaction. 12 A report of 16 cases of unexplained hemolytic anemia in 81 lung transplant patients found that these patients were significantly less likely to be immunosuppressed with mycophenolate mofetil (MMF) than azathioprine. 13 This unexplained presentation may indicate a possible auto or alloimmune pathogenetic mechanism for the development of this hemolytic anemia.
Microangiopathic hemolytic anemia. Microangiopathic hemolytic anemia is seen as a component of a syndrome known as thrombotic microangiopathy (TMA). This syndrome is characterized by varying degrees of the pentad composed of a Coombs negative hemolytic anemia, thrombocytopenia, acute renal failure, neurological disturbances, and fever. There are two entities, thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS), which are suspected to be different clinical manifestations of the same disease process. 14 The presence of TMA in transplant patient may be devastating; however, if this syndrome is promptly detected, it can be curable. In a review of 91 cases of hemolytic uremic syndrome in solid organ transplant recipients, it was seen that 90% were noted in renal transplant patients, 8% in liver, and 1% each in lung and heart transplant recipients. 14 The majority of cases occurred within the first year after transplant, with an overall mortality of 13%. The pathogenesis of TMA is thought to be related to endothelial injury and the initiation of microthrombi formation. This injury results in the release of endothelial ultra-large von Willebrand factor multimers that increase platelet adhesiveness and promote the formation of plateletfibrin thrombi in the microvasculature. In normal conditions, a metalloproteinase cleaves von Willebrand multimers into smaller fragments. However, patients with TMA have a deficiency or an inhibitor of this metalloproteinase. 15 Calcineurin inhibitors such as cyclosporine and tacrolimus are standard of care immunosuppressors in lung transplantation. These drugs have been shown to directly injure the endothelial cells initiating TMA. [16] [17] [18] Endothelin-1mediated vasoconstriction with further hypoxemia triggered by the aforementioned medications has been implicated as well. [19] [20] [21] TMA has also been described after lung transplantation and lung volume reduction surgery (LVRS) in patients treated with tacrolimus. 22 Although the side-effect profile and the spectrum of renal histopathologic changes appear to be similar in patients treated with cyclosporine and tacrolimus, these drugs are structurally unrelated and bind to different cytosolic proteins in target cells. This has been the rationale of the successful conversion of patients with cyclosporineassociated HUS to tacrolimus and vice versa. 23 CMV infection has been implicated as a risk factor for TMA. 15 It is thought that through direct infection or the initiation of an abnormal immune response, the endothelium is damaged and the sequence of events described above is triggered. [24] [25] [26] Several other complications post-lung transplantation have been identified as risk factors that may increase the rate of developing TMA, such as parvovirus B19 infection, 27 bacterial infection, acute rejection and valacyclovir. 28 Non-immune mediated hemolysis. Prophylaxis against eventual opportunistic infections became standard of care post-lung transplantation. 9 Trimethoprim/ sulfamethoxazole and dapsone are usually used in post-lung transplant patients for prophylaxis against pneumocystis pneumonia. In patients with deficiency of glucose-6-phosphate dehydrogenase (G-6-PD), which is an essential enzyme for assuring a normal red blood cells life span and for oxidizing processes, these medications may provoke the sudden destruction of RBCs and lead to hemolytic anemia.
Decrease in RBC production
Acquired red cell aplasia or hypoplasia in post-lung transplant patients is a phenomenon that can be associated with immunosuppressive and prophylactic medication, viral infections, or infiltrative disorders. 28, 29, 30 Drug-induced anemia. Immunosuppression and prophylaxis against opportunistic infections are the main treatments in post-lung transplant patients. The former therapy involves the use of one calcineurin inhibitor (cyclosporine or tacrolimus), steroids, and anti-lymphocyte therapy (MMF or azathioprine). In terms of prophylactic therapy for opportunistic infections, trimethoprim/sulfamethoxazole, dapsone, or atovaquone are used against Pneumocystis pneumonia while gancyclovir and valgancyclovir are used against CMV. Pure red-cell aplasia has been reported with cyclosporine, tacrolimus, and MMF. 29 In the US FK506 liver study 31 that compared cyclosporine and tacrolimus in regard to effectiveness of immunosuppressive therapy, the incidence of anemia was 38% in the cyclosporine group and 47% in the tacrolimus. A study that compared MMF with azathioprine in liver transplant recipients reported the presence of anemia as an adverse event in 43% of patients in the MMF group and 53% in the azathioprine group. 32 This complication was most likely related to bone marrow suppression.
The mechanism of anemia related to the use of trimethoprim/sulfamethoxazole involves folate deficiency and bone marrow suppression induced by these drugs. 32 These medications, as well as dapsone, are also responsible of cases of non-immune hemolytic anemia, especially in patients with G6PD deficiency, as it was mentioned earlier. Gancyclovir and valgancyclovir induce bone marrow suppression in 8%-25% of post-solid organ transplant patients. 28 However, a prompt recovery of RBCs is seen following the discontinuation of these drugs.
Virus-induced anemia. Certain viruses, such as Epstein-
Barr virus (EBV) and Cytomegalovirus have been implicated as a cause of anemia in transplanted patients. 32 The mechanism of action of EBV is thought to be the infection of bone marrow progenitor cells. A study reported findings of EBV genome and antigens in bone marrow cells of patients with aplastic anemia. 30 Unlike EBV, CMV infects bone marrow stromal cells. The cytopathic effect of CMV on stromal cells (i.e. fibroblast) changes the marrow microenvironment and then reduces the ability of the stromal layers to support the proliferation of progenitor cells. 32, 33 Post-lung transplant patients are exposed to parvovirus B19 reactivation, infection, or reinfection from the donor organ. Despite this numerous circumstances that permit infection after transplantation, the incidence of parvovirus B19 viremia is low, about 2%. 34 Anemia is the hallmark of parvovirus B19 infection. This virus infects the erythroid progenitor cells by binding to the receptor known as the P antigen. Then, subsequent parvovirus replication leads to cellular lysis that consequently is manifested as pure red-cell aplasia. The impairment in immunity that results from pharmacologic immunosuppression limits the ability of transplanted patients to produce neutralizing antibody. This lack of immunity leads to persistent parvovirus infection and chronic anemia.
Infiltrative disorders. Post-transplant lymphoproliferative disorder (PTLD) encompasses a heterogeneous group of lymphoproliferative diseases ranging from EBV-driven polyclonal proliferation of lymphocytes resembling infectious mononucleosis to highly aggressive monomorphic proliferation such as diffuse large B cell lymphoma. 35 The incidence of PTLD following lung transplantation is 1%-10% and it has been associated to bone marrow infiltration and immune hemolytic anemia. 31, 32 
Approach to diagnosis
The presence of anemia in a post-lung transplant patient should indicate to the treating physician that an underlying process is occurring. Although these patients are exposed to medications that might explain the presence of anemia, health care providers should not rely on this assumption and should pursue other etiologies to arrive promptly to the correct diagnosis. A practical method for organizing the many causes of anemia in post-lung transplant patients is to group them according to the reticulocyte count (Figure 1 ). If the reticulocyte count is elevated, the first step is to rule out a recent brisk bleeding. If bleeding is not evident, then hemolysis and its precipitants require consideration. The laboratory assessment includes a check of bilirubin, haptoglobin, and lactic dehydrogenase. Haptoglobin is the most sensitive but least specific because it is an acute-phase reactant. The peripheral smear showing schistocytes confirms the presence of microangiopathic hemolytic anemia. If immune-mediated anemia is suspected, direct and indirect Coombs should be undertaken. A drug-or infection-related episode of hemolysis in an African American patient should raise the question of G6PD deficiency, especially when the drug is trimethoprim/sulfamethoxazole or dapsone. A very low or absent reticulocyte count is suggestive of aplastic anemia. Current medication use and studies for viral infection may provide a clue to the diagnosis. Bone marrow biopsy is indicated if the condition persists after the possible drugs are halted.
Conclusions
Anemia is a common finding in post-lung transplant patients. Its presence suggests an underlying diagnosis that should always be pursued. Bone marrow suppression due to immunosuppressive medications is perhaps the most common cause of anemia. Other causes such as bleeding, microangiopathic thrombosis and immune-mediated anemia need to be treated promptly to avoid morbidity in these already susceptible patients.
